Project Grant HT94252410693
- This Project Grant award of $2,384,097, provided by the Defense Health Agency through the Military Medical Research and Development (CFDA 12.420) federal grant program, is funding a hybrid experimental clinical trial to determine the optimal sequencing of interventions to maximize the effectiveness of PTSD treatment. The primary awardee, The University of Texas Health Science Center at San Antonio, will conduct this research with a planned completion date of August 2028. The project involves two...
- This $2,763,615 federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a randomized controlled trial of brief prolonged exposure therapy for injured individuals admitted to a Level I trauma center. The goal is to evaluate the effectiveness of this approach in preventing post-traumatic stress disorder (PTSD) in this patient population. The 4-year study is being conducted by the Baylor Research Institute, a non-profit...
- This federal Project Grant award, valued at $3,141,404.00 and issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a randomized controlled trial to evaluate the efficacy of combined cognitive processing therapy and stellate ganglion blocks for the treatment of post-traumatic stress disorder (PTSD). The award was granted to Rush University Medical Center, a prominent academic medical center in Chicago, Illinois, to conduct this...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, a Project Grant of $2.34 million under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 29, 2029. The award supports a randomized controlled trial (RCT) examining the efficacy of the Man Therapy platform in reducing problematic anger among military service members,...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded $2.48M to the Veterans Medical Research Foundation of San Diego under the Military Medical Research and Development program (CFDA 12.420) to conduct a Phase 2A clinical trial evaluating the efficacy, safety, and tolerability of PT150 in treating posttraumatic stress disorder (PTSD) in U.S. military veterans. The award, issued September 30, 2025, with completion targeted for September 29, 2029, will deliver a randomized...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $6,964,861.00 to The University of Texas Health Science Center at San Antonio to conduct a multi-year longitudinal study focused on military psychological health. The study has five specific aims: Conduct a prospective, longitudinal follow-up of 3,360 previous clinical trial participants treated for PTSD, sleep disorders, or chronic pain. Conduct a...
- This $2,997,922 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund research at Florida State University (FSU) to develop rapid, non-invasive brain stimulation treatments for post-traumatic stress disorder (PTSD). The award, which runs from September 30, 2024 to September 29, 2028, will enable FSU's Sponsored Research Administration division to conduct cutting-edge scientific studies to advance...
- This $737,899 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will fund the development and evaluation of a nontrauma intervention to treat post-traumatic stress disorder (PTSD) in veterans and service members suffering from traumatic brain injury (TBI). The University of Texas Health Science Center at San Antonio, a state-controlled institution of higher learning, will lead the research effort over a 3-year...
- The U.S. Defense Health Agency awarded a $2,534,532 Project Grant to Rush University Medical Center to evaluate evidence-based options for initial PTSD treatment non-responders. This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports a comprehensive range of biomedical research initiatives aimed at improving health outcomes for military service members, veterans, and the broader public. The award has a performance period of September 1,...
- The Defense Health Agency has awarded a $1.632 million Project Grant to the Ocean State Research Institute, Inc., a non-profit research organization, to investigate the long-term outcomes of antipsychotic medication use in U.S. veterans with post-traumatic stress disorder (PTSD). This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform healthcare for service members and the public. As...
This federal Project Grant award of $2,993,024.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a randomized controlled trial of lethal means safety counseling for service members and civilians with post-traumatic stress disorder (PTSD). The study, titled "FIREARM SAFETY IN PTSD (FASP): A RANDOMIZED CONTROLLED TRIAL OF LETHAL MEANS SAFETY COUNSELING AMONG SERVICE MEMBERS AND CIVILIANS WITH PTSD", will be conducted by the University of Colorado-Denver, a major public research university, over a performance period from September 15, 2024 to September 14, 2028. The goal is to evaluate the effectiveness of lethal means safety counseling in reducing firearm-related suicide risk among individuals with PTSD, both in military and civilian populations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $3.0m | 6/12/24 |